Exportin (XPO1) inhibitors for the treatment of AML

Exportin (XPO1) inhibitors for the treatment of AML

VJHemOnc

2 years
396 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
Inhibitors of exportin (XPO1), a nuclear export chaperone, are currently in early clinical trials for acute myeloid leukemia (AML). Speaking from the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Ramiro Garzon, MD, from the Ohio State University, Columbus, OH, explains why these inhibitors are effective, referencing their effect on both tumor suppressor genes and oncogenes. Dr Garzon also shares preliminary findings from the clinical trials.
Up Next Autoplay